financetom
Business
financetom
/
Business
/
Short-seller Chanos questions bitcoin-holding pioneer Strategy's valuation premium
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Short-seller Chanos questions bitcoin-holding pioneer Strategy's valuation premium
Jun 12, 2025 12:32 PM

(Reuters) -Prominent short-seller Jim Chanos has questioned Strategy's valuation premium over its bitcoin holdings, saying Chairman Michael Saylor's tactics to boost the company's returns are "financial gibberish."

"...Mr. Saylor wants you to value his business based not only on the net value of his Bitcoin holdings (NAV) at market, but additionally with a multiple on the change in that NAV...," he said in a post on X on Tuesday.

Also, in an interview with Bloomberg Television on Wednesday, Chanos said that Strategy's market value should not exceed the value of its bitcoin holdings.

As of June 9, the company held 582,000 bitcoins, worth $62.27 billion, while its market value of $108 billion was about 1.74 times its crypto holdings.

Chanos and other Strategy critics have argued that this disconnect was creating an arbitrage opportunity for buying the cryptocurrency and shorting the firm's shares.

Strategy did not immediately respond to a Reuters request for comment.

MIMICKING STRATEGY

Following Strategy's footsteps, companies like GameStop ( GME ) and U.S. President Donald Trump's Trump Media & Technology ( DJT ) have also pivoted their operations to building bitcoin reserves.

Strategy's shares are up nearly 34% this year, eclipsing bitcoin's 14.2% climb.

Saylor has argued that critics overlook his company's innovative use of bitcoin-backed financial instruments, which he insists justify the premium at which the company trades and protect it from the risks Chanos highlights.

The company actively issues bitcoin-backed credit instruments, such as non-cumulative preferred stock, allowing it to raise capital without diluting common shareholders or taking on traditional debt obligations.

(Reporting by Ateev Bhandari in Bengaluru; Editing by Anil D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dollarama reports rise in quarterly sales on steady demand
Dollarama reports rise in quarterly sales on steady demand
Sep 11, 2024
Sept 11 (Reuters) - Dollarama ( DLMAF ) reported a rise in second-quarter sales on Wednesday, as inflation-weary customers rallied at its discount stores to shop for low-priced essentials such as groceries. The company's net sales rose 7.4% to C$1.56 billion ($1.15 billion) compared to a year ago. Analysts estimated net sales of C$1.57 billion, according to LSEG data. ($1...
Commerzbank on Overnight News
Commerzbank on Overnight News
Sep 11, 2024
07:02 AM EDT, 09/11/2024 (MT Newswires) -- Commerzbank in its European Sunrise note of Wednesday highlighted: Markets: United States Treasuries close near the highs, rally extends in Asia with long-end yields falling to their lowest levels since June 2023. US stocks recover into New York close, Asian stocks and e-minis retreat. Brent stabilizes around $69.50/barrel. US: 63% of viewers believe...
Arch Biopartners Receives Approval From Alberta Health Services to Proceed with Phase II Trial
Arch Biopartners Receives Approval From Alberta Health Services to Proceed with Phase II Trial
Sep 11, 2024
07:08 AM EDT, 09/11/2024 (MT Newswires) -- Arch Biopartners ( ACHFF ) on Wednesday said that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide, the company's leading drug candidate targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of Calgary Cumming School of Medicine is completing...
Xencor Prices $175 Million Public Stock Offering
Xencor Prices $175 Million Public Stock Offering
Sep 11, 2024
07:09 AM EDT, 09/11/2024 (MT Newswires) -- Xencor ( XNCR ) said Wednesday that it priced its underwritten public offering of about 6.6 million shares of its common stock at $18 per share and pre-funded warrants to buy up to about 3.1 million shares of common stock at $17.99 per pre-funded warrant for expected gross proceeds of about $175 million....
Copyright 2023-2026 - www.financetom.com All Rights Reserved